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1. ABSTRACT

The aim of this project is to develop a noninvasive serum test that predicts histologic
forms of myocarditis (inflammatory) and dilated (non-inflammatory) cardiomyopathy using
proteomic techniques to analyze serum proteins. Idiopathic dilated cardiomyopathy (DCM)
and myocarditis (myocardial inflammation) represent a spectrum of heart muscle disease of
various etiologies that usually present with progressive heart failure. Together, they
constitute the leading cause of heart transplantation in the United States. Currently, the gold
standard of diagnosis of myocarditis is by endomyocardial biopsy (EMB) and
histopathological classification according to the Dallas Criteria1; however this diagnostic
technique is severely limited by its invasiveness, a lack of sensitivity and an attendant
sampling error, yielding diagnostic information in only 10-20% of the cases2. As such, the
development of a non-invasive highly specific test for myocarditis is of great value and
importance particularly in the diagnosis of giant cell myocarditis, a rare but very fulminant
form

of

autoimmune

myocarditis

where

timely

institution

of

appropriate

immunosuppressive therapy significantly increases transplant-free survival.3
We proposed, using an observational case-control study, to undertake a proteomic
analysis to compare serum proteomic profiles - determined by mass spectroscopy and
isotope tagging- with histologic findings on endomyocardial biopsy. Our hypothesis is that
different forms of myocarditis and dilated cardiomyopathy have distinct serum protein
profiles and that these unique profiles which correlate with specific histologic types, will
allow for noninvasive diagnosis of major forms of myocarditis and DCM.
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2. SPECIFIC AIMS/HYPOTHESES

Idiopathic dilated cardiomyopathy and myocarditis together constitute the leading
cause of heart transplantation in the United States. Worldwide, approximately 45% of all
heart transplants are performed for IDC and up to 8% for myocarditis4. The current gold
standard of diagnosis with endomyocardial biology and classification by the Dallas criteria is
invasive - with a significant risk for major complications - and has low sensitivity and
specificity for diagnosis. In the patient with acute dilated cardiomyopathy, prognosis of
DCM varies with the histopathology found on biopsy. Thus, the central question addressed
by this project is: “are there noninvasive tests that can accurately predict histolopathology in
patients with acute cardiomyopathy?” Such tests would be of great benefit in clinical
management and the assessment of prognosis in patients presenting with acute
cardiomyopathy. We proposed to address this central question by testing the following
hypothesis:
We hypothesized - based on the distinct clinical and histopathology characteristics of
giant cell myocarditis (GCM), lymphocytic myocarditis (LM) and idiopathic dilated
cardiomyopathy (DCM) - that there are specific proteome modifications induced by or
associated with each disease state which results in differential expression of proteins in the
serum.
To test our hypothesis, we proposed the following specific aims:
Specific Aim 1: To reproducibly characterize the quantitative and qualitative changes in
serum protein expression in:
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i)

Acute giant cell myocarditis,

ii)

Acute lymphocytic myocarditis,

iii)

Idiopathic dilated cardiomyopathy

As compared to normal age and weight-matched controls.
Specifically, we used mass spectrometry based techniques for identification, isotope labeling
for quantification and biostatistical methods for multivariate analysis of differential protein
expression.
Specific Aim 2: To determine the sensitivity and specificity of the protein profiles for each
disease state and identify potential serum cardiac biomarkers, which could be applied in
novel diagnostic modalities, using statistical and biological correlation.
Our immediate emphasis in this part of the project, is on the characterization of the
quantitative and qualitative differences between serum proteins in the different disease
states. We proposed to determine the differences in the protein expression profiles in acute
LM, acute GCM and idiopathic DCM as compared to normal subjects using broad-based
proteomic screening techniques. Such differences would likely occur in up-regulation of
immune proteins including the inflammatory cytokines, up-regulation of membrane proteins
related to the formation of multinucleated giant cells in GCM, expression of viral proteins in
LM and in DCM, the dysregulation of cytoskeletal proteins such as actin, lamin, dystrophin.
Myosin light chain and other proteins linked to proven genetic mutations in DCM..
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3. BACKGROUND/SIGNIFICANCE

Myocarditis is defined as an inflammatory process of the muscular walls of the myocardium
which result in injury to the cardiac myocytes. Manifestations range from sub-clinical disease
to sudden death. Myocarditis in association with cardiac dysfunction is classified as
inflammatory cardiomyopathy and is usually caused by infections from viruses like
enterovirus and adenovirus etc., autoimmune diseases, or responses to toxic substances. It is
also thought to be a common cause of dilated cardiomyopathy and other cardiomyopathies5
from evidence of viral persistence in the myocardium in patients with idiopathic dilated
cardiomyopathy6.

Idiopathic dilated cardiomyopathy is a heterogenous classification

characterized by ventricular dilatation and diminished contractile function of unknown
etiology. It is usually a chronic and histologically is not associated with active inflammatory
infiltrates. In the USA, the estimated prevalence of DCM is 36.5 cases per 100,0007 and in a
review of 1230 cases of initially unexplained cardiomyopathy in the USA, 9% were thought
to be due to myocarditis8. There are several different histopathologic forms of myocarditis.
These include viral or lymphocytic myocarditis, most commonly due to adenoviruses like
coxsackie virus, enteroviruses and several other viral and bacterial agents. It is characterized
by interstitial lymphocytic infiltrates within the myocardium with little by way of myocardial
necrosis as shown in Figure 1 below.
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Figure 1: Lymphocytic Infiltrates in viral myocarditis. WebPath

Another distinct form of myocarditis is Giant Cell myocarditis, a form of autoimmune
myocarditis characterized by the presence of giant cells in the myocardium with areas of
myocyte necrosis and no signs of viral infiltration as shown in Figure 2 below.

Figure 2: Giant cells in the myocardium with areas of myocyte necrosis and
granuloma. WebPath.
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In idiopathic dilated cardiomyopathy, the molecular features can include myocyte
hypertrophy with myocyte degeneration and increased interstitial fibrosis.
Prognosis in myocarditis varies by histological type
Prognosis in myocarditis is dependent on the histological type diagnosed by biopsy and
classification according to the Dallas Criteria. For instance, the 5-year survival rate in
patients diagnosed with GCM is approximately 10% as compared with patients diagnosed
with lymphocytic myocarditis shown in the Kaplan-Meier survival curve below.

Figure 3,Transplant-free survival in GCM and LM. n=63 in GCM and n=111 in LM groups. P<.0001 by log-rank
test. From Cooper, et. al., N Engl J Med 1997 336:1860-66.

Early diagnosis and appropriate treatment improves transplant-free survival especially in Giant Cell
myocarditis (a rare but fatal autoimmune myocarditis) that requires immune suppression in addition
to standard heart failure treatment as shown in the Kaplan-Meier curve below. This unpublished data
from the GCM treatment trial showed a significant survival benefit for patients treated with a
regimen consisting of cyclosporine, azathioprine and OK-T3.
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Figure 4. Transplant-free survival in 11 GCM patients treated prospectively with cyclosporine-based
immunosuppression compared to 16 GCM historical registry patients treated with no immunosuppression or
steroids alone. p=.00026. All patients were diagnosed by biopsy.

Diagnosis of Myocarditis by Endomyocardial Biopsy and the Dallas Criteria
The gold standard in the diagnosis of myocarditis is by endomyocardial biopsy and
pathologic identification using the Dallas Criteria.9 However this diagnostic standard is
plagued by a lack of an attendant sampling error, a lack of sensitivity, and considerable
intraobserver variability in the identification of inflammatory infiltrates, yielding diagnostic
information in only 25% of cases.10

Figure 5: Right heart endomyocardial biopsy is gold standard for diagnosis of myocarditis. www.stanford.edu/biopsy
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The Myocarditis Treatment Trial reported poor concordance between the clinical diagnosis
of myocarditis and histopathological diagnosis from EMB with histopathologic evidence of
myocyte inflammation in only 214 of 2233 patients enrolled in the trial. Furthermore the
risks of biopsy include a 1 in 1000 risk of death and 1 in 250 risk of perforation in
experienced hands11 and also a risk of arrhythmias which preclude its routine clinical use. In
effect, EMB is increasingly viewed “tarnished” standard for diagnosis of myocarditis,
necessitating the development of better diagnostic standards12

Cardiac Biomarkers and Markers of immune up-regulation in myocarditis
There are several other biomarkers that have potential applicability in the clinical diagnosis
of myocarditis. Standard markers of myocardial damage including Troponin – I, CK-MB
have good specificity but limited sensitivity in the diagnosis of myocarditis. Lauer et al report
for Troponin I, a sensitivity for detecting myocarditis of 53%, specificity of 94%, a positive
predictive value of 93% and a negative predictive value of 56%13. Antibodies to a variety of
cardiac autoantigens such as myosin heavy chain, the β-adrenergic receptor, mitochondrial
antigens, and the adenosine diphosphate and triphosphate carrier proteins14 have also been
demonstrated in the sera of patients with acute myocarditis. Recent advances in the use of
PCR and the description of HLA typing for the diagnosis of myocarditis have furthered
diagnostic capabilities15. However, these techniques have limited clinical applicability due to a
lack of specificity and still require invasive testing, in most cases, to obtain the myocardial
tissue required for the tests.
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Change in Protein Expression in Myocarditis.
The pathogenesis of myocarditis is thought to occur via several different
mechanisms. These include a direct myocardial invasion by cardiotropic viruses, activation of
CD4 cells leading to clonal expansion of B cells and production of cardiac auto-antibodies or
the production of pro-inflammatory cytokines including IL-1, IL-2, TNF-∝and IFN-γ . In
essence, the acute injury to the myocardium is accompanied by distinct changes in the
protein expression profile and is more likely induce rapid post-translational modifications in
the proteins as compared to the co-translational changes that occur with altered gene levels
in chronic disease stated such as dilated cardiomyopathy16.

Figure 6: Pathogenesis of experimental autoimmune myocarditis varies in the acute, subacute and chronic
stages of myocarditis. Feldman and McNamara NEJM, 343 (19): 1388

Recent work on the gene expression in giant cell myocarditis myocardial samples, as
compared to normal hearts show an up-regulation in genes involved in immune response,
transcriptional regulation and metabolism17 suggesting that similar changes are likely in
protein expression.
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Figure 7; The gene expression profile in GCM is significant for a marked up-regulation in the immune
response genes in GCM as compared to normal. Kittleson, M.M et al, Int. J Cardio 102 (2005)

Clinical Proteomics in Myocarditis
Clinical proteomics involves the identification of protein patterns of disease in order to
improve patient care and public health through better assessment of disease susceptibility or
selection of therapy for the individual. The National Heart Lung and Blood Institute
(NHLBI) Clinical Proteomics Working Group18 identified an opportunity in the use of
modest numbers of well characterized clinical specimens for the discovery of such protein
markers. Proteomic analysis provides a mechanism for the broad-based screening of the
proteome to characterize the quantitative and qualitative modifications that are secondary to
each disease process. Previous work in the analysis of myocardial tissue from animal and
human models of cardiomyopathy have shown that the differential change in myocardial
proteins such as the myosin light chain. This and other changes in the failing heart
discovered through myocardial proteomics are cataloged online on the World Wide Web19.
Although there have been some advances made in tissue proteomics in cardiovascular
diseases, the proteomic analysis of the serum remains a novel approach in the investigation
of diagnostic, prognostic and therapeutic markers of cardiovascular disease.
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Given the ease of obtaining serum, and the widespread clinical use of other serum
biomarkers in cardiovascular disease, it holds promise for the discovery of novel biomarkers.
Recent advances in protein separation techniques, isotope tagging and increased sensitivity
of mass spectrometry now allow for broad-based screening of the serum proteome20. More
recently, classifications from the Human Proteome Organization (HUPO) have identified
cardiovascular-related proteins found experimentally in the human serum21 based on several
proteomics platforms. Of relevance is the grouping of these proteins putatively by functional
class into eight broad groups: markers of inflammation and/or cardiovascular disease,
vascular & coagulation, signaling, growth & differentiation, cytoskeletal, transcription
factors, channels/receptors and markers of heart failure. This provides the beginnings of a
serum proteomic blueprint for future development of new diagnostic and prognostic
markers for cardiovascular disease.
4. PRELIMINARY DATA

The research was conducted under the primary supervision of Dr. Leslie Cooper22 who has
an established interest and expertise in myocarditis research and has several current research
protocols on the treatment of myocarditis (Giant Cell Treatment Trial, IMAC trial.) The
team also included individuals with expertise in current proteomic technologies and
techniques in clinical proteomics (Dr. Sreekumar Raghavakimal, Ph.D. and Xuan-Mai
Persson of the Mayo Proteomics Core Facility).
State of the art proteomic research facilities and mass spectrometer were available through
the Mayo Proteomics core laboratory and the General Clinical Research Center (GCRC). In
addition, the team includes a biostatistician (Ann Oberg PhD) who had expertise in the
design and analysis of proteomic data and a Research Nurse, Annette McNallan is to assist
with the collection and coding of samples.
14

a. Proteomic comparison of plasma samples of GCM and normal control:
As proof of concept, we performed multidimensional liquid chromatography – quadrupole
time of flight mass spectrometry (LC/MS/MS) analysis on plasma samples of one patient
with GCM, one patient with DCM, one patient with LM and one normal control under a
feasibility study protocol. Briefly, the samples were separately filtered through a Microbead
separation column; the samples were labeled with an isotopic label, combined in equal
protein amounts after labeling and analyzed by mass spectrometry with LC/MS/MS.
Protein and peptides were identified using two separate and independent search engines
ProQuant (ABI) and MASCOT (Matrix Science) against the human non-redundant database.
Protein and peptide quantifications from the labeled isotopes were obtained through the
ProQuant software (ABI). Our results show the upregulation of inflammatory markers like
CRP and cytokines in the GCM group, as expected. In each sample, approximately 2800
unique proteins were identified with approximately 200 proteins differentially expressed at a
widely accepted arbitrary ratio of 1.2 or greater or a ratio of 0.8 or less.
Giant Cell Myocarditis vs. Normal Control Proein profiles

Ratios (116:114)

1000
100

CRP
Ratio 116:114

10
1
0.0001

0.001

0.01

0.1

1

0.1
Confidence Score

Figure 8: Difference in protein expression (ratios greater or less than one) between GCM and Normal controls
at different confidence scores (p-values) Ratio >1 is up-regulated, Ratio < 1 are down-regulated, p-value <0.05
is considered significant
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P Val 116:114

Ratio 116:114

0.0001

1.2456

Protein Name
hemopexin precursor

0.0001

1.3703

inter-alpha-trypsin inhibitor family heavy chain-related protein

0.0003

0.7645

Afamin precursor (Alpha-albumin) (Alpha-Alb)

0.0004

0.6965

gelsolin isoform b

0.0006

0.7131

proapolipoprotein

0.0011

0.6081

Inter-alpha-trypsin inhibitor heavy chain H2 precursor (ITI heavy chain H2) (Inter-alpha-inhibit or h)

0.0012

1.414

0.0023

0.5505

similar to hypothetical protein
alpha2-HS glycoprotein

0.0027

0.5951

Serotransferrin precursor (Transferrin) (Siderophilin) (Beta-1-metal binding globulin) (PRO 1400)

0.003

2.2001

Plasma protease C1 inhibitor precursor (C1 Inh) (C1Inh)

0.0096

1.4609

Complement component C9 precursor

0.0099

1.3213

Unnamed protein product

0.0118

4.4887

alpha1-antichymotrypsin

0.0123

1.2789

complement component 6

0.0133

0.7846

A Chain A, Antithrombin Iii

0.0136

0.6324

Insulin-like growth factor binding protein, acid labile subunit

0.0143

0.6147

A Chain A, Serum Amyloid P Component (Sap)

0.0203

0.7793

Thyroxine-binding globulin precursor (T4-binding globulin)

0.0205

9.8728

CRP protein

0.0267

2.3294

B Chain B, Cleaved Alpha-1-Antitrypsin Polymer

0.0331

1.2829

complement component 5

0.0504

0.5871

Tetranectin precursor (TN) (Plasminogen-kringle 4 binding protein)

Table 1: Select protein expression ratios and p-values in a patient with GCM (116:114, ratio of GCM to
Control) and a normal control, run twice (114 and 117). Inflammatory markers like CRP and complement are
significantly elevated in disease subjects versus control.

5. STUDY DESIGN AND METHODS

Study Design:
This is an observational case-control study with matched cases and controls conducted in
two phases. We studied:
•

10 cases of biopsy-proven giant cell myocarditis (GCM),

•

10 cases of biopsy-proven lymphocytic myocarditis (LM) and

•

10 cases of biopsy-proven idiopathic dilated cardiomyopathy (IDCM),

•

10 normal controls
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GCM Acute
(Day 1)
Samples
GCM
Convalescent
(Day 30)
Samples

Pairwise
Comparison of
protein
expression
profiles in same
patient

PHASE I

GCM Acute Samples
LM Acute Samples
IDCM Acute Sample

Fourplex
Comparison of
protein
expression
Profiles

Pooled Normal
Controls

PHASE II

Each case was compared to a normal age and sex matched control. Given the inherent
biological variations in serum protein profiles described with age, sex and body habitus, we
controlled for these factors by one-to-one matching to minimize bias in our analysis. Cases
were examined as a matched set for proteomic analysis using 4-isotope labeling. To minimize
the effects of isotope-isotope interaction, isotope labels were randomly assigned to each
disease or normal grouping.

Power and Sample Size:
Given the rarity of the conditions under study and the difficulty in ascertaining an effect size
a priori, the calculation of sample size in this design is dependent on a back-calculation from
the total number of cases available for study. Thus, with a study design of 10 patients in
each group, and an estimated effect size of 1.2 or 0.8, with a co-efficient of variation of 80,
we can achieve 80% power at 0.05 p-value. For the multivariate analysis of protein
expression, we will consider a lower p-value of 0. 01 to account for multiple hypothesis
testing.
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Figure 9: Relationship between sample size, variation and sample power.

Study Population:
Samples for the Proteomic analysis had already been obtained as part of previous research
protocols and the project was approved by the IRB at the Mayo Clinic. All subjects had
given written informed consent for their samples to be stored and used in the study of other
disease conditions. Serum samples were available from patients with giant cell myocarditis,
lymphocytic myocarditis and idiopathic dilated cardiomyopathy both in the acute and posttreatment phases of disease with corollary clinical data also available on the course of
disease. Serum samples with similar storage time frames were also available from age and
weight-matched normal controls for comparisons. The use of age and weight matched
controls in this case was done to reduce the biologic variations in the proteome associated
with those factors. This study used subjects with stored serum samples from previous Mayo
Clinic protocols. The relevant protocols include:
2186-04 A Phase 1, Open-Label. Pilot Study to Assess the Safety of Immunoadsorption
Using the Fresenius Immunoabsorba for Chronic Dilated Cardiomyopathy, L Cooper PI
2288-03 Genetic Modulation of LV Recovery Project, L Cooper PI
468-02 The Role of Autoantibodies and Cytokines in Myocarditis, L Cooper PI
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754-00 Thromboangiitis Obliterans (Buerger’s Diseases) Registry, L Cooper PI
147-99 A Multicenter Randomized Study to Evaluate the Efficacy of Monomurab-CD3, in
Subjects with Giant Cell Myocarditis, L Cooper, PI
1792-03 UNIPATH study normal controls.
Inclusion Criteria:
We included subjects with the following criteria in the study:
•

Biopsy proven cases of DCM, LM (by Dallas Criteria), IDCM

•

Subjects with stored serum samples obtained during the acute phase of disease
(i.e. within 7 days of diagnosis and before the institution of immuno-modulatory
treatment)

•

Age greater than 18 years

•

Written informed consent available for use of samples.

Research Methods:
There are 3 major sequential steps in the proteomic analysis of serum which we employed in
this study.

Step 1: Sample Preparation:
Protein Depletion: Given the complexity of the proteins in the plasma and the wide dynamic
range of concentrations -- greater than 10 orders of magnitude -- it is important to simplify
the composition of serum through protein depletion. This allows for the detection of lowabundance proteins after the removal of the 12 most abundant proteins that account for
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95% of the protein content of the serum.
The protein depletion was done using Genway Biotech’s Seppro Microbead-conjugated
avian IgY antibodies to specifically remove human serum albumin, IgG, IgA, IgM,
transferrin, fibrinogen, apolipoprotein A-I, apolipoprotein A-II, haptoglobin, α-1 antitrypsin,
α-1 acid glycoprotein and α-2 macroglobulin23. The use of this system allowed for the
recovery of all three separate fractions of proteins in the serum as shown below. Each
fraction was analyzed separately, starting with the least abundant protein fraction, to
characterize the full spectrum of serum protein.

Protein Sample

Microbead
Separation Column

90% most abundant
proteins

Non-specifically
bound proteins

5% least abundant
proteins

Labeling
Tryptic Digest

Figure 10: Protein Separation Schema

Isotope Labeling: Briefly, 100µg of protein post-depletion from each serum sample was
separately reduced, denatured, cysteine blocked and tryptic digested according to the Applied
Biosystems (ABI) iTRAQ protocol. The 4 samples were labeled with the 114, 115, 116 and
117 isotope iTRAQ reagents according to the randomization plan as described in the study
design section. The samples are combined after labeling for further analysis on the mass
spectrometry.
20

Step 2: Liquid Chromatography/Mass Spectrometry analysis (LC/MS/MS)
Following combination of the fractions, the peptides were fractionated on a strong cation
exchange column prior to introducing to a capillary LC/MS/MS system (Ultimate, LC
packings and QSTAR ABI.) Independent data acquisition from each fraction is obtained
using the Analyst QS system.

Figure 11: QStar ABI Mass Spectrometer, and graphical representation of a sample fraction after analysis on
mass spect.

Step 3 : Protein Identification and Quantification:

Figure 12: Mass Spectrometry Analysis of differential protein expression using in-vitro isotope tagging.24
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Protein Identification:
Following the analysis of the samples on the mass spectrometry, the data obtained (peptide
mass fingerprint after tandem MS/MS) was reconstructed into its parent peptide sequence
and queried against known protein databases – SEQUEST and MASCOT using the Applied
Biosystems (ABI) proprietary ProQuant software25. We chose to use this software because it
qualifies the identified protein in a non-redundant score, assigning confidence scores (pvalues) to the proteins such that species with higher scores have a higher likelihood of being
present in the analyte and are easily identified. To validate our system, we will analyze the
known fraction of specifically bound proteins (from the protein separation step) as an
internal control.
Protein Quantification:
The quantification of various protein expression levels in our experimental set-up was
carried out by analyzing the quantities of the isotope-tagged fragment of each protein.
Isotope tagging was done using the proprietary iTRAQ system. This involves the use of an
isobaric mass tag attached to a peptide reactive group (PRG). The isobaric tag is actually
composed of a reporter mass and a balance mass which makes it isobaric. The reporter
masses vary from 114 to 117, producing 4 separate masses that allow for the comparison of
up to four separate samples simultaneously.

Figure 13: iTRAQ chemical tagging schema. http://www.proteome.soton.ac.uk/iTRAQ
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The peptide reactive group attaches to the C terminal of the amino acid, thus attaching the
isotope tag to all amino acids in the sample of interest. Following combination of the
samples and mass spectrometry analysis, the unique fragmentation pattern identifies the
peptide sequence in question, whilst the reporter or mass ions give a measure of the
abundance of the peptide/protein species in the samples as shown in Figure 14 below.

Figure 14: Principles of isotope tagging using iTRAQ. http://www.proteome.soton.ac.uk/iTRAQ.htm

This information is contained in the ProQuant analysis and is expressed as a ratio of a given
tag to a pre-selected baseline tag, which is usually chosen to correspond to the normal
control. Proteins are grouped into four categories from this analysis:
i.

up-regulated (ratio >1.2)

ii.

down-regulated (ratio <0.8)

iii.

absent in patient but present in control

iv.

present in patient but absent in control.
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To validate the identification and quantification of the protein data obtained from the
ProQuant Analyst software, we will use an independent protein analysis software, the iTracker26 (open source : www.i-Tracker.com) to query the non-redundant databases and
determine the accuracy of our analysis by correlation studies.
Statistical Analysis:
Specific Aim 1: To characterize the qualitative and quantitative changes in the serum
expression profiles, we used two analytical methods:
Univariate Analysis - Average of Ratios: One dimensional analysis of the average change
in the expression of proteins will be done by determining the average ratios of expression of
a given protein across all ten sets of experiments (provided that the bias or error scores are
similar between sets.) To normalize the distribution and provide a robust analysis of the
ratios, conversion to the log space is necessary, as shown below.

Figure 15: Transformation of ratios into log space for univariate analysis

Multi-dimensional analysis: The simple analysis of ratios fails to take into account the
correlation between the expression levels of various proteins within the same disease state or
amongst normal subjects i.e. it is likely that the changes in protein expression levels are
correlated to a panel of proteins rather than a change in a single protein. Furthermore, the
inherent biological variation can confound the ability to conclude that any differences are
due to the true changes in the protein expression27. Thus to analyze this, we will use
dimensional scaling or a dimensionality reduction procedure, primarily principal components
24

analysis (based on the pooled data on all subjects.)
This technique, which does not require prior knowledge of the disease state (i.e. blinded
analysis) involves calculating the distance between individual samples in n –dimensional
space using a variety of matrices such that similar samples cluster close to each other and
dissimilar samples cluster far away. Using this scaling, one can test whether the group means
for the multi-dimensional scaling coordinates are different among groups, using standard
Multivariate ANOVA measure like a Hotelling T test.
Specific Aim 2:
To evaluate the sensitivity and specificity of the serum protein markers identified by
profiling, boosted decision tree analysis and Euclidean distance vectors can be used to
determine specific proteomic patterns. To ascertain the biological relevance of the
differences in expression profile, we will do protein expression pathway analyses, localization
and functional annotation to delineate the importance of the proteins within the metabolic
pathway. These analyses can be performed on human proteins using the appropriate
software (Pathway analysis from MetaCore, Pathway assistance from Stratagene and
functional annotation from KEGG.)

Oyere K. Onuma performed all the experiments presented below, including the sample
preparation and data analysis. The mass spectrometer was operated in the Proteomics Core
Laboratory, Mayo Clinic Rochester. Biostatistical support was also provided by the
Department of Biostatistics, Mayo Clinic Rochester.
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RESULTS:
Protein separation using the Seppro column was reproducible.

Albumin

Figure 16: 1-D Gel showing serum fractions pre- and post- depletion

In the figure above, the depletion of the 12 most highly abundant proteins using the Seppro
affinity column is highly consistent and reproducible. In the two end lanes in the gel shown
above , the whole un-fractionated serum shows a heavy albumin signature. However postdepletion (lanes 2-14) albumin is markedly depleted, allowing for the appearance of less
abundant proteins in the serum profile.
GCM (ACUTE VS. CONVALESCENT)
In Phase I studies, we compared serum samples in acute Giant cell myocarditis as compared
to convalescent myocarditis. Serum samples from eight patients with histopathologic and
clinical diagnosis of giant cell myocarditis were included in an observational case-control
study in self-matched pairs. Briefly, the serum samples were separately filtered through an
antibody-affinity microbead separation column; trypsinized, isotope labeled, combined and
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analyzed by tandem mass spectrometry. Proteins with a fold change of 20% were defined as
differentially expressed and pathway analysis of differential proteins was performed by
comparison with published protein groupings. Of more than 600 differentially regulated
proteins across the eight sets, there was marked up regulation in acute GCM of immune and
defense proteins (n=217) such as C-Reactive Protein and the Complement proteins. Proteins
involved in lipid, fatty acid and steroid metabolism, such as the apolipoproteins show
significant down regulation in acute GCM as shown in Figure 17. Pathway analysis of 43
common differentially expressed proteins also highlighted activation of the immune

Differential Protein Expression
250
200
150
100
50
0
-50
SIGDUCT

NUCLEOSIDE

LIPID/STE

IMNDEF

CARB_METB

APOP

-100

AA_METB

Number of proteins up- or down-regulated

response and lipid metabolism molecular pathways.

Figure 17. : Number of known proteins upregulated or downregulated in serum of acute versus convalescent patients with
giant cell myocarditis classified by molecular function. AA_METB, amino acid metabolism; APOP, apoptosis;
CARB_METB, carbohydrate metabolism; IMNDEF, immunity and defense; LIPID/STE, lipid, fatty acid and steroid
metabolism, NUCLEOSIDE, nucleoside, nucleotide and nucleic acid metabolism, SIGDUCT, signal transduction.

When compared to previous results on GCM gene expression from work done by Kittleson
et al, our results show an interesting concordance with the marked up-regulation in immune
defense proteins across platforms (gene expression versus proteomics) and also across
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biological samples (tissue versus serum) as shown below, thus validating the serum proteomics

Differential Protein Expression
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Select Differentially Regulated Proteins in Acute Vs. Convalescent GCM.
Immunity and Defense

Complement mediated immunity

–

Complement component 4a

–

–

C9 complement protein

Complement C4A precursor

–

–

complement C3d/Epstein-Barr virus receptor precursor - human

Complement 4B proprotein

–

–

immunoglobulin J chain

Complement C3 precursor

–

–

complement component 1, q subcomponent, gamma polypeptide

Complement C5 precursor

–

–

Complement component C9 precursor

Beta-2-glycoprotein I precursor (Apolipoprotein H)

–

–

Complement component C7 precursor

Complement factor H precursor

–

CRP protein

B-cell and antibody-mediated immunity

Lipid, Fatty Acid and Steroid Metabolism

–

proapo-A-I protein

–

–

proapolipoprotein

anti-HBsAg immunoglobulin Fab kappa chain

–

–

apolipoprotein D, apoD

immunoglobulin lambda light chain VLJ region

–

–

lipoprotein Gln I

Ig L-chain V-region

–

–

Apolipoprotein E precursor (Apo-E)

Ig heavy chain, variable region

–

Hypothetical protein (Fragment)

–

Ig kappa chain variable region

Apolipoprotein A-IV precursor (Apo-AIV)

–

–

immunoglobulin kappa chain variable region

–

Retinoic acid receptor RXR-gamma
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Pathway Analysis
Pathway analysis was done using the MetaCore Pathway Analysis program. This is a web-based
software for molecular pathway analysis. It allows for the analysis of proteomic software in the
context of known molecular and metabolic pathways.

Preliminary Pathway analysis of the

differentially regulated proteins in acute vs. convalescent GCM was significant for the highlighting
the immune defense pathways and the lipid metabolism pathways., suggesting that these pathways
might play a significant role in the pathogenesis of giant cell myocarditis.

GCM Acute Vs. Convalescent : Network2 -- GRB14, CRP,
DDR1, EDD, Ubiquitin
29

PHASE II - GCM VS.LM VS. NORMAL VS. IDCM (Preliminary Results)
In our phase II experiments, we undertook a fourplex comparison of Giant Cell Myocarditis
(GCM), Lymphocytic Myocarditis (LM), Idiopathic Dilated Cardiomyopathy (IDCM) and
Normal Controls. Having shown a difference between acute and convalescent GCM in the
Phase I studies, the experimental design for this set of experiments was geared to identify a
unique fingerprint, if present, for GCM as compared to other forms or etiologies of acute
heart failure. Preliminary results for an N=3 are presented below (See figure annotation in
Figure above)
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Differential Protein Expression GCM vs. LM
Number of proteins up- or down-regulated
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The preliminary results are significant for a variety in the protein expression profiles in the
different disease profiles. For instance, the marked up-regulation in immune defense
proteins observed in the phase one studies is muted in the comparisons between GCM and
Normal, GCM and LM, GCM and DCM, suggesting that these conditions do indeed show
unique protein profiles that can form the basis for discerning unique protein markers for
DCM using the statistical tools described above. Furthermore, we expect to see a less
pronounced difference in the protein expression profiles due to the influence of biologic
variability.
Pathway Analysis GCM vs. DCM vs. LM vs. Normal Controls
Following analysis of the 6 experimental sets together, we obtained the following results: For
each experimental set, we were able to identify
•

107,000 m/z peaks per MS run

•

2400 differentially expressed peptides
o Redundant and single occurrence peptides removed

Using the Proquant analysis program, the differentially regulated proteins identified
from these peptides were obtained and used as Metacore input.
Differentially Regulated Pathways - MetaCore
GCM vs LM

36

GCM vs DCM

12

GCM vs Normal

14

32

Top 10 Differentially Regulated Pathways GCM Vs. LM Vs. DCM Vs. Normal

Classic complement pathway
Plasmin signaling
Alternative complement pathway
ZNF202 in atherosclerosis gene expression
Slit-Robo signaling
Lectin induced complement pathway
Catherin mediated cell adhesion
ECM remodeling
TGF, WNT and cytoskeleton remodeling
Rho GTPase regulation of actin/cytoskeleton

GCM vs DCM
GCM vs Normal
GCM vs LM
In particular, we focused on the differentially regulated pathways between GCM and LM, we
see a statistically significant change in the classic complement pathway, Slit-Robo signaling
pathway and the Rho GTPase regulation of the actin/cytoskeleton pathways (identified as
pathways 1, 5 and 10 above). They are significantly upregulated in GCM as compared to LM.
The upregulation of the immune response complements GCM in this comparison suggest
the same type of immune dysregulation seen in our Phase I GCM Acute vs. Convalescent
pathways. These pathways as shown below are biologically relevant in the pathogenesis of
GCM.
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Classic Complement Pathway (GCM vs. LM)
In the Actin pathway, we see an upregulation of the cytosleletal proteins in GCM as
compared with LM as shown in the pathway below. This again suggests a measure of
cytoskeletal dysfunction occurs in the pathogenesis of GCM. However, when we examine
the Slit-Robo Pathway, there seems to be a potential link, mediated by the fyn pathway
between the immune dysregulation represented in the complement cascade and the
cytoskeletal dysfunction in the Actin pathway. Of note, the fyn pathway also appeared to be
significant in our analysis of GCM acute vs. convalescent.
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GCM vs Lymphocytic Myocarditis Rho GTPases and the Actin Cytoskeleton

Slit-Robo Signaling (fyn pathway) in GCM vs. LM
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Discussion:
Analysis of the differentially regulated proteins in both the GCM Acute vs.
Convalescent studies and the GCM/LM/DCM studies was significant for the
highlighting of the Fyn pathway. Fyn is 59kDa protein, a member of the src-family
of tyrosine kinases which has a structure similar to the other family members: an Nterminal attachment site for saturated fatty acid addition, a unique region, a srchomology 3 SH3 and SH2 domain, a tyrosine kinase SH1 domain and a C-terminal
negative regulatory domain. The domain structure allows for both tyrosine kinase
function and an adapter function for larger macromolecules through the SH2 and
SH3 domains as shown below.

The Fyn protein is expressed as two isoforms, one isoform Fyn T is expressed in T
cells while the other Fyn B is expressed in brain and other tissues. This differential
expression allows for further localization of the identified Fyn protein by its
presumed origin. Thus the identification of Fyn-T in our sample is specific for
augmented T cell activity in the samples from Giant Cell myocarditis.
Fyn has a variety of biologic functions, including T cell signaling, B cell development,

development of brain function, mitogenic signaling and cell adhesion mediated
signaling. Of most biological relevance in this context is the role of fyn in T cell
receptor signaling. Animal studies and cell line studies both indicate a critical role for
fyn in proximal T-cell antigen receptor (TCR) signal transduction. It is implicated in
pre-TCR signaling, positive selection, peripheral maintenance of naïve T cells and
also in lymphopenia-induced proliferation28. Overexpression of the fyn(T) transgene
is thought to produce an enhanced responsiveness to TCR signaling which might
account for the increases susceptibly to autoimmunity observed in mouse models.
When the fyn knockout is introduced into MPR/lpr mice, manifestations of
autoimmunity are reduced and the mouse live longer29. Mutations in a number of
signaling components in mice can lead to strong autoimmune phenotypes. Fyndeficient mice exhibit a number of immunological abnormalities and also exhibit
some autoimmunity30
Thus, it is likely that fyn is important in the pathogenesis of autoimmue myocarditis
as manifested in GCM and might present an appropriate target for the development
of diagnostic and treatment modalities.
The identification of the fyn pathway in our analysis represents one mechanism
through which proteomic analysis can aid in the a priori identification of important
mechanisms in disease and potential therapeutic and prognostic targets. However,
further verification of the role of fyn in the pathogenesis of GCM needs to be
carried out. We are currently working on this using in-situ hybridization to localize
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the presence of fyn in GCM myocardial tissue as compared to normal myocardium
to confirm that fyn is indeed a specific marker of possible T cell dysregulation in
GCM.31

Strengths and Limitations:
Strengths:
The strengths to our approach lie in using proteomics to provide diagnostic and
mechanistic insight into the pathophysiology of myocarditis. To our knowledge, this
is a novel application of quantitative serum proteomics in the analysis of various
histologic forms of myocarditis and dilated cardiomyopathy and it holds a lot of
promise. In particular, it

helps to examine the obvious, but as yet unproven,

hypothesis that these distinct disease entities (by histopathology and etiology) will
produce unique protein signatures. Clinically, it also provides an important novel
approach to the care of the patient with acute cardiomyopathy by allowing for new
diagnostic test panels based on the unique protein profiles that identify the specific
histologic form, without the need for an invasive heart biopsy.
This approach also holds the potential for providing new mechanistic insights into
the pathogenesis of myocarditis and cardiomyopathy since it allows for an unbiased
look at the entire proteome to identify previously unknown protein changes in a
disease or condition.
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Limitations:
Given the high level of biological variability inherent in the plasma samples and
technical variability in sample preparation and analysis, the ability to reproducibly
measure a myriad of protein expression changes across numerous multivariate
experiments is a key challenge in many proteomics experimental designs32.
Specifically in the study of a relatively rare condition like myocarditis, sample size is
limited by the number of available cases such that the ability to increase study power
is also limited. However, in this project, we have addressed this variability using
different techniques:
i)

Biological Variability: We employed one-to-one matching of case to
controls to reduce the confounding variables of age, sex, BMI and length
of serum storage. Furthermore, in the GCM Acute vs. Convalescent
studies, the use of self-matched controls in the study design minimized
the level of biological variability in the comparison.

ii)

Technical Variability:
a. Randomization of matched sets to different isotope tags to prevent
isotope-effect
b. Independent validation of the proprietary protein identification and
quantification platform Pro Quant using the i-Tracker system to
search against the database.
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iii)

Statistical Variability:
a. Blinding of statistical analyst (not privy to information on diseases vs.
non-diseased samples) during the clustering analysis reduces the risk
of bias in the grouping of expression profiles by similarity.

6. HUMAN SUBJECTS
This project conforms to the Mayo Clinic Foundation guidelines relating to research
risks when human subjects are involved. These risks are less applicable to this study
since it is a minimal-risk protocol that involves the use of stored samples and no
direct patient contact.

7. CONSENT
This study met the criteria for waiver of HIPAA authorization and informed
consent. No consent forms were required.

8. CONCLUSION
Our results suggest that the identification of

unique serum protein profiles

associated with specific forms of acute cardiomyopathy is feasible using a strategy
that does not require a priori identification of protein candidates. In our phase one
studies, we have demonstrated a novel finding in possible role of altered immune
response as well as altered lipid metabolism pathways in GCM. Furthermore, we
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have demonstrated that GCM may be distinguished from LM by altered regulation
of pathways involving the Fyn tyrosine kinase and actin cytoskeletal proteins and
other immune regulatory pathways. However the further validation of protein
candidates is required through biochemical assays, repeat proteomic assays and in the
future, prospective in vitro studies is required in order to make any definitive
conclusions about unique serum proteins in GCM. However, this implies that serum
protein profiles may provide a unique protein signature for GCM. This strategy may
ultimately allow for more selective use of EMB or for the noninvasive diagnosis of
giant cell myocarditis.

- 41 -

9. FUTURE DIRECTIONS

Hypothesis
Phenotypic Assessment
•
•

Experimental Design

Sample preparation

Cell Culture Models
Transgenic animal
d l

Biochemical Analysis
•
•

Protein Expression
Molecular
I
i

HPLC/Mass Spectrometry

Protein ID databases

Identification & Validation
of Candidate Proteins

Figure 18: Strategies for hypothesis-driven proteomics

Future work on this project will involve the refining of the original hypothesis using
the information on viable protein candidates obtained from this stage of the project.
Thus far, we have worked on creating the hypothesis, experimental design, sample
preparation, HPLC/Mass spectrometry and the identification and validation of
protein candidates. To complete the flow of hypothesis-driven proteomics, there is a
need to carry out further biochemical analysis and phenotypic studies. There is also a
need to develop more robust statistical tools, especially for the non-linear analysis of
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quantitative proteomic data. These are the directions that we hope to work on in the
near future
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